Novo Nordisk Pharma AG
http://www.novonordisk.ch
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk Pharma AG
COVID-19 Gives US Biopharma Plenty Of Q1 Cover
Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.
Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales
The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.
Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.